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Abstract 
The question of whether or not neutron therapy works has been answered. It is a 
qualified yes, as is the case with all of radiation therapy. But, neutron 
therapy has not kept pace with the rest of radiation therapy in terms of beam 
delivery techniques.  Modern photon and proton based external beam radiotherapy 
routinely implements image-guidance, beam intensity-modulation and 3-
dimensional treatment planning. The current iteration of fast neutron 
radiotherapy does not. Addressing these deficiencies, however, is not a matter 
of technology or understanding, but resources.   
The future of neutron therapy lies in better understanding the interaction 
processes of radiation with living tissue. A combination of radiobiology and 
computer simulations is required in order to optimize the use of neutron 
therapy. The questions that need to be answered are: Can we connect the 
macroscopic with the microscopic? What is the optimum energy? What is the 
optimum energy spectrum? Can we map the sensitivity of the various tissues of 
the human body and use that knowledge to our advantage? And once we gain a 
better understanding of the above radiobiological issues will we be able to 
capitalize on this understanding by precisely and accurately delivering fast 
neutrons in a manner comparable to what is now possible with photons and 
protons? 
This presentation will review the accomplishments to date. It will then lay 
out the questions that need to be answered for neutron therapy to truly be a 
21st Century therapy. 
 Introduction 
Fermilab’s first director, Robert Wilson, first proposed hadron therapy in 1946 
[1]. Fast neutron therapy began in the United States through a series of grants 
in the early 1970s from the National Cancer Institute to approximately eight 
facilities around the country [2]. In most cases, each facility was an add-on 
to an existing physics laboratory and used the beam and beam energy peculiar to 
that facility. Interest in offering neutron therapy at Fermilab grew out of a 
presentation by Louis Rosen, of the Los Alamos Scientific Laboratory, at the 
1971 Particle Accelerator Conference and subsequent discussions among Chicago 
area physicians and physicists [3]. 
 
After Rosen’s talk, local physicians and physicists began discussions to 
start hadron therapy in the Chicago area. Prof. Lester Skaggs of the University 
of Chicago and the Argonne Cancer Hospital organized these discussions looking 
into protons, ions, and pions. It is unclear what caused the shift from these 
particles to neutrons, but on September 7, 1976, the first patient was treated 
at the Cancer Therapy Facility, later named the Neutron Therapy Facility (NTF), 
at Fermilab with neutrons. 
Why Neutrons 
The primary reason supporting the use of neutrons for therapy is their relative 
biological effectiveness (RBE). For the neutron energies supplied by the NTF 
beam, 1/3 less dose is required to achieve the same clinical effect with 
neutrons as is required with conventional photons. However, this is not the 
complete story as there is probably no clinical advantage to using such a beam 
if the final outcome were exactly the same as with photons.  Certain tumours 
are classified as being radioresistant. They respond very poorly to 
conventional photon therapy. In these cases, neutrons are more effective, 
beyond just the factor of three in RBE (see Table 1)[4]. A partial explanation 
is that conventional radiation therapy relies on the creation of oxygen free 
radicals to provide the lethal effect. Radioresistant tumours tend to be 
hypoxic which inhibits the creation of radicals. Neutrons on the other hand do 
not rely on radicals and therefore are less dependent on the oxygenation of the 
tumour. But even this does not completely explain a neutron’s RBE. Other 
mechanisms are at work that are not completely understood. 
In addition to fast neutron therapy, a new opportunity is appearing, 
neutron capture therapy (NCT). This is a binary therapy where a neutron 
absorbing agent is attached to a drug that is preferentially taken up by tumour 
cells. When exposed to neutron radiation, the agent absorbs a neutron and 
undergoes a radioactive decay. The energetic by-products of the decay provide a 
localized boost of dose to the tumour area in addition to the dose from the 
neutron radiation itself. The two agents presently being investigated are 
boron-10 (BNCT) and two isotopes of gadolinium, 155 and 157, (GdNCT). 
  
 Table 1: Review of the loco-regional rates for malignant salivary gland tumors 
treated with radiation therapy. 
 
The Fermilab Setup 
At Fermilab, the neutron beam is produced by bombarding a beryllium target with 
protons. The Neutron Therapy Facility is located approximately a third of the 
length of the proton linac used as the injector for Fermilab’s High Energy 
Physics program. As the linac pulses at 15 Hz, a fast 58° dipole magnet can 
divert linac pulses into the NTF beam line. A second 32° dipole magnet 
completes the 90° bend. Quadrupole magnets maintain the focus of the beam in 
the 12 foot long beam line and direct the beam onto the target. At the point 
where the beam is diverted from the linac, the proton energy is 66 MeV. The 
beryllium target is 49 MeV thick or 2.21 cm and is 2.5 cm in diameter (see 
Figure 1). It is backed by 0.05 cm of gold and placed in an aluminium holder 
which is 0.32 cm thick in the beam direction. The latter two elements ensure 
that all the protons have ranged out so that only photons and neutrons escape 
the target. 
A primary collimator of steel with a conical opening of 7.5° is immediately 
downstream of the target assembly. This followed by a transmission chamber 
which is used to monitor the flux of neutrons generated. The neutrons then 
enter the therapeutic collimator assembly. This contains interchangeable 
collimators of either a concrete/polyethylene matrix or polyurethane that have 
various rectangular openings. The proper choice of one of these collimators 
determines the size of the field to be used for treatment. These collimators 
are 78 cm long. To better conform the outline of the neutron field to the shape 
of the tumour to be treated, blocks, 20 cm long, made from low carbon steel are 
placed in the opening of the collimator. 
  
 Figure 1: NTF Target and Collimation 
 
While the beam is fixed in the horizontal plane, treatment is able to be 
delivered in an isocentric manner by moving the patient. The patient either 
stands or sits on an immobilization platform that rotates in front of the beam 
opening. The platform can translate along, and transversely to, the beam axis 
allowing the placement of the tumour above the centre of rotation of the 
platform. This allows the tumour to be irradiated from multiple angles 
throughout the treatment while remaining fixed at the isocentric distance of 
190 cm. 
A Matter of Scale 
While trying to understand how neutrons, and all radiation for that matter, 
truly interact to cause their damage, one is faced with the drastic range of 
distance scale involved. This is apparent in both conducting physical 
measurements and in simulations. Macroscopic measurements, with distance scales 
of centimetres or millimetres are easily achievable in both cases. 
The conventional wisdom is that linear energy transfer (LET), in the 
context of double-strand breaks in the DNA, is the key to understanding the 
killing power of neutrons. This wisdom, in effect, assumes that LET is a linear 
value that can somehow be varied over orders of magnitude with an optimum value 
at 100 keV/µm. This value of LET happens to match well with the distance scale 
of the double helix of DNA. Despite a criticism that will be mentioned shortly, 
this means that we need to understand the interactions of fast neutrons and 
matter on a distance scale of a few nanometres. This is in contrast with the 
distance scale of BNCT where the range of fission products of the boron atom is 
7.3 µm and 4 µm for the alpha and lithium ions respectively, whereas the range 
of the Auger electrons from gadolinium decay is again a few nanometres. 
The Connection to Chemistry and Biology 
It is becoming apparent that simple DNA breakage is not sufficient in 
understanding the killing power of ionizing radiation. A broader understanding 
 of the ways ionizing radiation can disrupt cellular processes is needed [5]. We 
previously mentioned RBE as a factor in determining the need for neutron 
therapy along with LET and double-strand breaks. However, this understanding, 
particularly of LET, is not completely adequate for describing the impact of 
neutrons. Radiobiologist Shirley Lehnert provides this critique of LET: “LET is 
a simplistic way to describe the quality of different types of radiation since 
it fails to address the size of the individual energy-loss events that occur 
along the track of a particle.” [6] Understanding “the size of the individual 
energy-loss events” could very well be the key in understanding the difference 
between photon, neutron, and light-ion initiated events. Simulations of the 
radiation/matter interactions on scales comparable to the biological processes 
involved will be necessary to truly understand and exploit ionizing radiation. 
The Role of Simulations 
In this paper we only report on our own efforts in simulating the NTF beam. 
MCNPX [7] was chosen because of past experience with the style of input format 
used in operating the code. Very early on we had the benefit of comparing some 
initial results with GEANT 4 [8][9] and that work served to validate our 
initial efforts and give us some assurance that we were operating the code 
correctly (Figure 2). 
Figure 2: Comparison of MCNPX and GEANT4 results showing proton energies after 
passing through beryllium and gold of target assembly  
 
Our work with MCNPX has been useful in understanding the macroscopic 
evolution of the neutron energy as it passes through the system. Much of our 
work has been focused on finding ways to moderate our fast neutron beam so that 
it is better suited to NCT. We have tried various filtration schemes to try to 
 maximize the production of epithermal neutrons (Figure 3). This figure shows 
the neutron energy spectrum at the exit of the clinical collimation system 
(yellow). After exiting the collimator the beam is then simulated to pass 
through either 10 cm of lead (purple) or 10 cm of tungsten (dark blue). 
Alternately, the figure shows the results of the neutron passing through 
alternating 1 cm thicknesses of lead and tungsten, with a total of 5 cm each 
(cyan). The goal of this work is to generate a neutron spectrum that retains 
enough penetrating power to reach deep tumours and yet moderate in energy as 
they pass through tissue so that the energy is low enough for capture once they 
encounter the enhancing compound in the tumour. However, we are not able to see 
what happens at scales smaller than a few millimetres.  
Figure 3: Simulation of neutron spectra leaving collimator system (input 
spectra) and after passing through 4 cm of lead and/or tungsten to optimize 
neutron production in epithermal range. 
 
As mentioned above, a challenge in NCT is having enough penetrating power 
to reach deep tumours. Figure 4 shows the range of neutrons of various initial 
energies (Figure 4). This shows that neutrons with initial energies below 100 
keV cannot contribute to a clinical dose at depth. This has implications for 
both fast neutron therapy and NCT. For fast neutron therapy, it would be 
advantageous to remove these neutrons from the incident beam as they only 
contribute to higher risk for complications. For NCT, it places a limit on the 
lower edge of the energy spectrum that we hope will moderate, as it penetrates 
tissue, to near thermal energies by the time they reach the tumour. 
  
 Figure 4: The 1/e attenuation distance of mono-energetic neutrons striking A150 
plastic. 
Future Needs 
There are many applications waiting for accurate simulations of the interaction 
of radiation with matter at the nanometer level. Physics, chemistry and biology 
can all benefit from this development. The effective treatment of cancer and 
other diseases need an understanding of the magnitude and type of interactions 
that occur. Are certain chromosomal structures more or less susceptible to 
damage? What kind of radiation induces this damage? How do the interactions of 
the recoil fission products of BNCT interact differently than the dense Auger 
electron shower of GdNCT? Do fast neutrons produce different secondary ionizing 
radiation depending on their energy? 
Once answered, this knowledge can be entered into optimization routines for 
treatment planning systems. Instead of plotting dose deposition, actual killing 
power can be visualized. Target structures can be enhanced and sensitive 
tissues can be avoided. 
Then we will truly have a 21
st
 Century therapy. 
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